GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (NAS:REVB) » Definitions » Cash Flow from Financing

REVB (Revelation Biosciences) Cash Flow from Financing : $12.85 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2024, Revelation Biosciences paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Revelation Biosciences spent $0.00 Mil on financial activities for the three months ended in Dec. 2024.


Revelation Biosciences Cash Flow from Financing Historical Data

The historical data trend for Revelation Biosciences's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Cash Flow from Financing Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
- 8.01 15.20 14.03 12.85

Revelation Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 5.42 - 3.74 3.69

Revelation Biosciences Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Revelation Biosciences's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

Revelation Biosciences's Cash from Financing for the quarter that ended in Dec. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revelation Biosciences  (NAS:REVB) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Revelation Biosciences's issuance of stock for the three months ended in Dec. 2024 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Revelation Biosciences's repurchase of stock for the three months ended in Dec. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Revelation Biosciences's net issuance of debt for the three months ended in Dec. 2024 was $0.00 Mil. Revelation Biosciences received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Revelation Biosciences's net issuance of preferred for the three months ended in Dec. 2024 was $0.00 Mil. Revelation Biosciences paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Revelation Biosciences's cash flow for dividends for the three months ended in Dec. 2024 was $0.00 Mil. Revelation Biosciences received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Revelation Biosciences's other financing for the three months ended in Dec. 2024 was $0.00 Mil. Revelation Biosciences received $0.00 Mil on other financial activities.


Revelation Biosciences Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Revelation Biosciences Business Description

Traded in Other Exchanges
N/A
Address
4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Executives
George F Tidmarsh director, 10 percent owner
Lakhmir S Chawla director 1960 KIRBY ROAD, MCLEAN VA 22101
Axa Im Prime Impact Gp S.a.r.l other: Former 10% owner 2-4, RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Im Prime Impact Master Fund I Sca Sicav-raif other: Former 10% Owner 2-4 RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Investment Managers S.a. other: Former 10% owner 6 PLACE DE LA PYRAMIDE, TOUR MAJUNGA, PUTEAUX I0 92800
Axa Investment Managers Paris other: Former 10% owner 6 PLACE DE LA PYRAMIDE, PUTEAUX I0 92800
Axa Investment Managers Uk Ltd other: Former 10% owner 22 BISHOPGATE, LONDON X0 EC2M 3XJ
S.a. Axa other: Former 10% owner 25 AVENUE MATIGNON, PARIS I0 75008
Jess Roper director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
James Rolke director, officer: Chief Executive Officer 10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Curt H Labelle director C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Jennifer Carver director 725 NEWPORT STREET, DENVER CO 80220
Zygmont Chester Stanley Iii officer: Chief Financial Officer 3322 MILLIKIN AVE, SAN DIEGO CA 92122
Lawrence Feis 10 percent owner 190 EAST WALTON PLACE, UNIT 603, CHICAGO IL 60611
Feis Equities Llc 10 percent owner 20 NORTH WACKER DRIVE, SUITE 2115, CHICAGO IL 60606